Home › Esophageal Adenocarcinoma › Illinois
Esophageal Adenocarcinoma clinical trials in Illinois
11 studies for Esophageal Adenocarcinoma are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago8 studies
- Evanston6 studies
- Waukegan4 studies
- Joliet3 studies
- Arlington Heights3 studies
- Springfield3 studies
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 37 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- and 54 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0379, Chicago
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Illinois Cancer Specialists, Arlington Heights
- Illinois CancerCare - Bloomington, Bloomington
- Illinois Cancer Specialists, Chicago
- and 7 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- City of Hope Cancer Center-Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Northwestern Memorial Hospital, Chicago
Recruiting
Ages 18 to 89 · All sexes · Updated Sep 11, 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Chicago
- Research Site, Niles
- Research Site, Zion
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Ingalls Family Care Center, Calumet City
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- and 13 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Northwestern University, Chicago
Recruiting
Ages 18 to 89 · All sexes · Updated Jul 1, 2026 · NCT05530343From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.